Ali ÇELİK, Yetkin AĞAÇKIRAN, Ertan AYDIN, Nurettin KARAOĞLANOĞLU, Ülkü YAZICI

Thymic carcinoid with multiple endocrine neoplasia type 1: a case report

Timik karsinoid, timusun nadir görülen nöroendokrin tümörüdür. Sporadik olgular dışında, sıklıkla multipl endokrin neoplazi tip 1 (MEN1) ile ilişkilidir. Göğüs ağrısı yakınması ile başvuran ve dev timik karsinoid ile ilişkili MEN1 olan 39 yaşında erkek bir olguda, toraks bilgisayarlı tomografisinde (BT) çapı 10 cm olarak ölçülen sol göğüs boşluğuna taşan ön medi- astinal kitle izlendi. Bilgisayarlı tomografi eşliğinde yapılan perkütanöz tru-cut biyopside timusun karsinoid tümörüne rastlandı. Tümör sol torakotomi ile çıkarıldı. Örneklerin patolojik incelemesinde sıklıkla lokal peri- kardiyal doku invazyonu ile kapsüle timik karsinoid tümöre rastlandı. Ailesel MEN1 izlenen olgu son yedi aydır asemptomatik idi. Timik karsinoid, MEN1 görü- len olgularda başlıca ölüm nedenlerindendir. Erken tanı ve hastalığın tedavisi, morbidite ve mortalite risklerini en aza indirebilir.

Tip 1 multipl endokrin neoplazi ile timik karsinoid: Olgu sunumu

Thymic carcinoid is a rare neuroendocrine tumor of the thymus. Apart from sporadic cases, it is usually associated with multiple endocrine neoplasia type 1 (MEN1). Thoracic computed tomography (CT) revealed an anterior mediastinal mass with a size of 10 cm in diameter, encroaching into the left thoracic cavity in a 39-year-old male case with MEN1- related giant thymic carcinoid who was admitted due to chest pain. A computed tomography-guided percutaneous tru-cut biopsy demonstrated a carcinoid tumor of the thymus. Tumor was resected through left thoracotomy. Pathologic analyses of the specimen revealed thymic carcinoid tumor, mostly encapsulated with local pericardial tissue invasion. The patient with familial MEN1 was asymptomatic for the past seven months. Thymic carcinoid is the leading cause of death in patients with MEN1 disease. Early diagnosis and treatment of this condition would help to minimize morbidity and mortality rate.

PDF

___

1. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001;12:173-8.
2. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.
3. Brandi ML. Multiple endocrine neoplasia type 1. Rev Endocr Metab Disord 2000;1:275-82.
4. Wilkinson S, Teh BT, Davey KR, McArdle JP, Young M, Shepherd JJ. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993;128:683-90.
5. Ferolla P, Falchetti A, Filosso P, Tomassetti P, Tamburrano G, Avenia N, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 2005;90:2603-9.
6. Gibril F, Chen YJ, Schrump DS, Vortmeyer A, Zhuang Z, Lubensky IA, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003;88:1066-81.
7. Schnirer II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol 2003;42:672-92.
8. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9:66-76.
9. Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC. Thymic carcinoid in multiple endocrine neoplasia 1: genotype- phenotype correlation and prevention. J Intern Med 2006;259:428-32.
10. Zarnegar R, Brunaud L, Clark OH. Multiple endocrine neoplasia type I. Curr Treat Options Oncol 2002;3:335-48.
11. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck- Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
12. Rosai J, Higa E. Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. Cancer 1972;29:1061-74.
13. Rosai J, Higa E, Davie J. Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association. Cancer 1972;29:1075-83.
14. Teh BT, Zedenius J, Kytölä S, Skogseid B, Trotter J, Choplin H, et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998;228:99-105.
15. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 1999;134:1119-23.
16. Falchetti A, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle: University of Washington; 1993-2005 Aug 31 [Updated 2010 Mar 2].
17. Granberg D, Skogseid B. Lung and thymic neuroendocrine tumors. In: Doherty G, Skogseid B, editors. Surgical endocrinology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 413-30.
18. Hirai S, Hamanaka Y, Mitsui N, Kumagai H, Kobayashi T. Thymic carcinoids in multiple endocrine neoplasia-type 1. Jpn J Thorac Cardiovasc Surg 2001;49:525-7.
19. Dotzenrath C, Goretzki PE, Cupisti K, Yang Q, Simon D, Röher HD. Malignant endocrine tumors in patients with MEN 1 disease. Surgery 2001;129:91-5.
20. Farley DR, van Heerden JA, Grant CS. Are concomitant surgical procedures acceptable in patients undergoing cervical exploration for primary hyperparathyroidism? Mayo Clin Proc 1991;66:681-5.
21. Filosso PL, Actis Dato GM, Ruffini E, Bretti S, Ozzello F, Mancuso M. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg 2004;127:1215-9.
22. de Montpréville VT, Macchiarini P, Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg 1996;111:134-41.